XBI SPDR S&P Biotech ETF
- 90.075
- +1.935+2.20%
Twist Bioscience Launches MGF Product, Stock Climbs 10%
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43%. Currently, Moderna has a market capitalization of
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Top ETFs With the Most and Least Options Activity - Barclays
Crinetics Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 61.88% JMP Securities → $80 Reiterates Market Outperform → Market Outperform 05/07/2024 96.28%
Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been delayed.
Moderna Announces Delay in RSV Vaccine Review in U.S.
Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last y
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Earnings Call Summary | Revolution Medicines(RVMD.US) Q1 2024 Earnings Conference
The following is a summary of the Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript:Financial Performance:Revolution Medicines reported a net loss of $116.0 million or $0.70 per share
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Baird raise
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 -23.57% Mizuho $223 → $235 Maintains Neutral 05/03/2024 6.67% RBC Capital $332 → $328 Maintains
Revolution Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 20.07% Needham → $46 Reiterates Buy → Buy 04/12/2024 17.46% Oppenheimer $43 → $45 Maintains Out
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Cathie Wood's Ark Invest Purchases Over $30M of Shopify Shares Amid Q1 Numbers-Driven Plunge; Adds Reddit Shares To Kitty — Offloads Coinbase Stock As Bitcoin Declines
On Wednesday, Cathie Wood's Ark Invest made some significant trades. The most prominent among these were the purchases of Shopify Inc (NYSE:SHOP) and Reddit Inc (NYSE:RDDT), and the selling off of Coi
Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.75) by 6.67 percent.
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome TrialData from Phase 3 P